Merck’s Knockout Cubist Bid Should Fend Off Rivals

Updated on

Merck & Co.’s offer for Cubist Pharmaceuticals Inc. may be just steep enough to deter rival bidders.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.